Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer

NCT06001749 is registered in ClinicalTrials.gov with Yvan Beaussant, MD, MSci as lead sponsor.

NCT NCT06001749
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06001749 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer
Lead sponsor
Yvan Beaussant, MD, MSci
Phase
Phase 2
Overall status
Recruiting
Start date
September 23, 2024
Completion date
December 31, 2026
Enrollment
15 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, advanced cancers, opioid-related disorders, pain management, pain management and care